Thiogenesis Therapeutics, Corp. (TSXV:TTI)
Canada flag Canada · Delayed Price · Currency is CAD
0.7100
+0.0100 (1.43%)
Oct 1, 2025, 10:29 AM EDT

Thiogenesis Therapeutics Income Statement

Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
1.51.361.040.930.310.08
Research & Development
3.762.224.161.081.370.5
Operating Expenses
5.263.585.212.011.670.6
Operating Income
-5.26-3.58-5.21-2.01-1.67-0.6
Interest Expense
----0-0-0
Interest & Investment Income
0.120.20.170.01-0
Currency Exchange Gain (Loss)
0.050.23-0.03---
Other Non Operating Income (Expenses)
---0.10.46-
EBT Excluding Unusual Items
-5.09-3.15-5.06-1.91-1.22-0.61
Other Unusual Items
----2.01--
Pretax Income
-5.09-3.15-5.06-3.92-1.22-0.61
Net Income
-5.09-3.15-5.06-3.92-1.22-0.61
Net Income to Common
-5.09-3.15-5.06-3.92-1.22-0.61
Shares Outstanding (Basic)
464539251210
Shares Outstanding (Diluted)
464539251210
Shares Change (YoY)
8.65%15.93%54.71%118.86%15.56%-
EPS (Basic)
-0.11-0.07-0.13-0.16-0.11-0.06
EPS (Diluted)
-0.11-0.07-0.13-0.16-0.11-0.06
EBIT
-5.26-3.58-5.21-2.01-1.67-0.6
Source: S&P Global Market Intelligence. Standard template. Financial Sources.